Publication | Closed Access

A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers

OncologyMedicineBiliary CancerAdvanced Biliary CancersOsi-7904l Versus 5-FluorouracilFirst-line TreatmentAnti-cancer AgentCancer TreatmentPharmacologyRadiation Oncology